Navigation Links
Generex to Participate in Canadian Diabetes Association Conference

WORCESTER, Mass., Oct. 20 /PRNewswire/ -- Generex Biotechnology Corporation (Nasdaq: GNBT, today announced that it will be attending the 13th Annual Canadian Diabetes Association (CDA) ( / Canadian Society of Endocrinology and Metabolism (CSEM) ( Professional Conference and Annual Meetings in Edmonton, Alberta.  The gathering will run from October 20-23, 2010 at the Shaw Conference Centre (9797 Jasper Avenue Northwest, Edmonton).

At booth 437/536, Generex will provide the internationally renowned community of educators, clinicians, and scientists in attendance the chance to learn about the Company's advancements in the field of diabetes.  Information and one-on-one Q&A opportunities will be available on Generex Oral-lyn™, the Company's buccal insulin spray, as well as our proprietary consumer product, Glucose RapidSpray™ (

"This conference is an excellent forum for exchanging ideas and experiences with our peers about how to advance diabetes treatments to the next level," said Mark Fletcher, the Generex Interim President & Chief Executive Officer.  "We are particularly looking forward to show-casing Generex Oral-lyn™, which is in the late stages of a global, pivotal Phase III clinical trial."  

Highlights of the conference will include speaker forums addressing current diagnosis and treatment issues, interactive workshops, oral abstract sessions, poster presentations, a trade show, and sponsored social activities.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  The Company's buccal insulin spray product, Generex Oral-lyn™, which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  For more information, visit the Generex website at or the Antigen Express website at

Safe Harbor Statement

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts.  Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not.  Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement.  No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.  Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials.  Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency.  Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Generex Reschedules Live Video Webcast
2. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
3. Generex Announces That Adjournment Will be Sole Matter Considered at Reconvened Special Meeting of Stockholders on October 15, 2010
4. Generex Provides Clarification for Special Meeting Voting
5. Generex Reaches Agreement to Acquire 51% Stake in Global Medical Direct, a Nationwide Durable Medical Equipment and Pharmaceutical Provider Specializing in Direct-to-Consumer Diabetes Supplies
6. Generex Biotechnology Provides a Corporate Update to Address Managements Strategic Initiatives for Growth
7. Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System
8. Generex Presents Abstract at EASD Annual Meeting
9. Generex Announces Sales Agreement with Elias Shaker & Company
10. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
11. Generex Announces Presentations of Novel Vaccine Strategies
Post Your Comments:
(Date:12/1/2015)... , BANGALORE, India and ... N.V. (NASDAQ, TASE: MYL) today announced that it expects ... and for developing country markets funded by international donors, ... mg + Efavirenz 400 mg) for $99 per patient, ... Initiative (CHAI) to develop TLE400. The significantly reduced price ...
(Date:12/1/2015)... CARLSBAD, Calif. , Dec. 1, 2015 ... medicine products and services, announced today that it has ... care services organization. Members served by Novation will have ... therapy devices, sports bracing products and soft goods dedicated ... --> The aging U.S. population, rising ...
(Date:12/1/2015)... 2015 Building on its 25-year legacy ... (NYSE: JNJ ) today announced four new ... significantly reduce the burden of HIV incidence, especially ... of new HIV infections among adolescents in sub-Saharan ... these new initiatives include collaborations with the U.S. ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 02, 2015 , ... ... events and association with initiation of treatment for osteoporosis ”. , As corresponding ... pharmacological treatment in patients diagnosed with osteoporosis. Based on a large US managed ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an article published ... discrimination claim against the U.S. Department of Health and Human Services, claiming that any ... plans are breaking the clause in the law prohibiting the denial of coverage for ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of ... has been named by MedEsthetics magazine as the Best Single Physician Practice in the ... the many elite aesthetic physicians honored by the industry publication. , Dr. Vitenas ...
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... in the 1980s we have seen vast improvements in scientific research and discoveries, ... significant strides, providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic ... United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a ... catastrophic contributors to diseases of the diabetic foot. The American Board of ...
Breaking Medicine News(10 mins):